Last reviewed · How we verify

RAGWEED 12 AMB A 1-U — Competitive Intelligence Brief

RAGWEED 12 AMB A 1-U (RAGWEED 12 AMB A 1-U) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allergen extract immunotherapy. Area: Immunology / Allergy.

marketed Allergen extract immunotherapy Ragweed pollen allergens (Amb a 1 and related epitopes) Immunology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

RAGWEED 12 AMB A 1-U (RAGWEED 12 AMB A 1-U) — Clinique Spécialisée en Allergies de la Capitale. Ragweed pollen extract allergen immunotherapy that desensitizes the immune system to ragweed allergens through repeated controlled exposure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
RAGWEED 12 AMB A 1-U TARGET RAGWEED 12 AMB A 1-U Clinique Spécialisée en Allergies de la Capitale marketed Allergen extract immunotherapy Ragweed pollen allergens (Amb a 1 and related epitopes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allergen extract immunotherapy class)

  1. Clinique Spécialisée en Allergies de la Capitale · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RAGWEED 12 AMB A 1-U — Competitive Intelligence Brief. https://druglandscape.com/ci/ragweed-12-amb-a-1-u. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: